XML 56 R45.htm IDEA: XBRL DOCUMENT v3.10.0.1
Collaborative Arrangements - Narrative (Details) - USD ($)
$ in Millions
1 Months Ended 3 Months Ended 6 Months Ended 12 Months Ended 35 Months Ended
Jan. 31, 2021
Jan. 31, 2020
Jan. 31, 2019
Mar. 31, 2018
Jan. 31, 2018
Jul. 31, 2017
Jun. 30, 2018
Mar. 31, 2018
Jun. 30, 2017
Jun. 30, 2018
Jun. 30, 2017
Dec. 31, 2017
Jan. 31, 2021
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                          
Research and development             $ 2,274   $ 1,782 $ 5,470 $ 3,612    
Other liabilities, noncurrent             12,028     12,028   $ 11,117  
Sales             10,465   $ 9,930 20,502 $ 19,365    
AstraZeneca                          
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                          
Upfront and milestone payments           $ 1,600              
Payments to acquire intangible assets           750           250  
Research and development                       2,350  
Contingent milestone payments collaborative arrangement           6,150              
Total consideration collaborative arrangement (up to value)           8,500              
AstraZeneca | Lynparza                          
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                          
Amortization expense             $ 17 $ 9          
Amortization period             10 years            
AstraZeneca | Regulatory Milestones                          
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                          
Upfront and milestone payments         $ 70                
Contingent milestone payments collaborative arrangement           2,050       1,980      
AstraZeneca | Sales-Based Milestones                          
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                          
Contingent milestone payments collaborative arrangement           $ 4,100       3,650      
Probable contingent payments collaborative arrangement             $ 200            
Other liabilities, noncurrent       $ 150     $ 200 150   200   100  
Eisai                          
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                          
Upfront and milestone payments       750                  
Research and development                   1,400      
Eisai | Forecast                          
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                          
Payments to acquire intangible assets $ 125 $ 200 $ 325                   $ 650
Eisai | Lenvima                          
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                          
Amortization period             9 years            
Eisai | Regulatory Milestones                          
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                          
Upfront and milestone payments       25                  
Contingent milestone payments collaborative arrangement       385                  
Eisai | Sales-Based Milestones                          
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                          
Contingent milestone payments collaborative arrangement       $ 3,970                  
Bayer AG | Adempas                          
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                          
Amortization expense             $ 106            
Amortization period             9 years 6 months            
Sales                       $ 500  
Bayer AG | Sales-Based Milestones                          
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                          
Upfront and milestone payments               $ 350          
Contingent milestone payments collaborative arrangement                   400      
Probable contingent payments collaborative arrangement             $ 375            
Other liabilities, noncurrent             $ 375     $ 375